ASCO 2025 – BioNTech shows promise in mesothelioma
BNT327 could rival Keytruda and Opdivo, but toxicity is worth watching.
ASCO 2025 – J&J challenges its own multiple myeloma T-cell engagers
Meanwhile, Ichnos Glenmark takes a different trispecific multiple myeloma approach.
ASCO 2025 – Amgen gets one over on Zai Lab
Imdelltra seems headed for full approval, raising questions about Zai’s accelerated plan.
ASCO 2025 – J&J takes another prostate cancer shot
The company highlights the safety of its KLK2-targeting T-cell engager pasritamig.
ASCO 2025 – BioNTech’s latest Claudin6 effort falls short
BNT142 looks lacklustre, but the company still sees promise in mRNA-encoded bispecifics.
Pfizer bets big on a bispecific
The company is paying $1.25bn for a PD-1 x VEGF project, the largest deal here yet.
Takeda says no to B7-H3
TAK-280 is among the group's discarded projects, although it’s a T-cell engager, not an ADC.
Amgen takes Imdelltra front line
Dellphi-312, testing Imdelltra plus PD-(L)1, will start mid-year.
